You may have noticed that Prolynx scientists value publishing their novel research in high-quality, peer-reviewed-journals. We are proud to be the sole non-academic group recognized as one of the "selected highly-prolific authors" in the past 5 years for Bioconjugate Chemistry on their Journal Stars website: http://journalstars.acs.org/biological/journal/bioconjugate-chemistry.
44) Carreras, C. et al. Long-Acting Poly(ADP-ribose) Polymerase Inhibitor Prodrug for Humans. Bioconjugate Chem 35(4), 551-558. (2024)
43) Santi, D.V. et al. Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors? BioDrugs, https://doi.org/10.1007/s40259-024-00643-8. (2024)
42) Fontaine, S. et al. A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors. Cancer Res Commun, 3(5): https://doi.org/10.1158/2767-9764.CRC-22-0517 (2023)
41) Del Pozo, V. et al. PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma. iScience, 25, 1-15. (2022)
40) Thomas, A. et al. PLX038: A Long-Acting Topoisomerase 1 Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors. Mol Cancer Thera, 21(11), 1722-1728. (2022)
39) Schneider, E. et al. A long-acting C-natriuretic peptide for achondroplasia. PNAS, 119(30), e2201067119. doi.org/10.1073/pnas.2201067119. (2022)
38) Hangasky, J.A. et al. A very long-acting IL-15: implications for the immunotherapy of cancer. J Immunother Cancer, 10, e004104. doi:10.1136/jitc-2021-004104. (2022)
37) Hearn, B. et al. Attenuation of the Reaction of Michael Acceptors with Biologically Important Nucleophiles. Bioconjugate Chem. 32, 794-800. (2021)
36) Santi, D. et al. Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both? Annals of Translational Medicine, 9(14):1113. https://dx.doi.org/10.21037/atm-21-1103. (2021)
35) Henise, J. et al. Facile preparation of tetra-polyethylene glycol hydrogel microspheres for drug delivery by cross-flow membrane emulsification. Engineering Reports, e12412. https://doi.org/10.1002/eng2.12412. (2021)
34) Fontaine, S. et al. A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. Cancer Research, 81(4), 1076-1086. (2021)
33) Hangasky, J.A. et al. Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink. Frontiers in Immunology, 11(1813). doi: 10.3389/fimmu.2020.01813. (2020)
32) Henise, J. et al. High-throughput, aseptic production of injectable Tetra-PEG hydrogel microspheres for delivery of releasable covalently bound drugs + SI. Engineering Reports, https://onlinelibrary.wiley.com/doi/full/10.1002/eng2.12213. (2020)
31) Guilu, S. et al. Prospective use of the single-mouse experimental design for the evaluation of PLX038A. Cancer Chemotherapy and Pharmacology, 85, 251-263. (2020)
30) Schneider, E. et al. A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. Domestic Animal Endocrinology, Vol 70, 106373. (2020)
29) Henise, J. et al. Autoclave sterilization of tetra-polyethylene glycol hydrogel biomaterials with b-elimination crosslinks. Engineering Reports, https://doi.org/10.1002/eng2.12091 (2019)
28) Beckford Vera, D. et al. PET imaging of the EPR effect in tumor xenografts using small 15 nm diameter polyethylene glycols labeled with zirconium-89. Molecular Cancer Therapeutics, DOI: 10.1158/1535-7163.MCT-19-0709. (2019)
27) Fontaine, S. et al. PLX038: a PEGylated prodrug of SN-38 independence of UGT1A1 activity. Cancer Chemotherapy and Pharmacology, https://doi.org/10.1007/s00280-019-03987-z. (2019)
25) Fontaine, S. et al. Species-specific optimization of PEG~SN~38 prodrug pharmacokinetics and antitumor effects in triple-negative BRCA1-deficient xenograft. Cancer Chemotherapy and Pharmacology, https://doi.org/10.1007/s00280-019-03903-5. (2019)
24) Henise, J. et al. In Vitro-In Vivo Correlation for the Degradation of Tetra-PEG Hydrogel Microspheres with Tunable β-Eliminative Crosslink Cleavage Rates. International Journal of Polymer Science, Vol. 2019, Article ID 9483127. (2019)
23) Fontaine, S. et al. PLX038: A long-acting prodrug of SN-38 and enhancer of the DNA Damage Response. Gordon Conference. (2018).
22) Machinaga, N. et al. A Controlled Release System for Long-Acting Intravitreal Delivery of Small Molecules. TVST, Vol. 7, No. 4, Article 21. (2018)
21) Hearn, B. et al. Primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system. Journal of Controlled Release, 278, 74-79. (2018)
20) Schneider, E. et al. A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP‑1 Receptor Agonist. ACS Chemical Biology, 12, 2107-2116. (2017)
19) Schneider, E. et al. Approach For Half-Life Extension of Small Antibody Fragments That Does Not Affect Tissue Uptake. Bioconjugate Chemistry, 27, 2534-2539. (2016)
18) Henise, J. et al. Surgical Sealants with Tunable Swelling, Burst Pressures, and Biodegradation Rates. Journal of Biomedical Materials Research B, 1058(6), 1602-1611. (2016)
17) Cerchiari, A.E. et al. Probing the Luminal Microenvironment of Reconstituted Epithelial Microtissues. Scientific Reports, 6,33148; doi: 10.1038/srep33148. (2016)
16) Schneider, E. et al. Subcutaneously Administered Self-Cleaving Hydrogel-Octreotide Conjugated Provide Very Long-Acting Octreotide. Bioconjugate Chemistry, 27, 1638-1644. (2016)
15) Schneider, E. et al. Hydrogel Drug Delivery System Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide. Bioconjugate Chemistry, 27, 1210-1215. (2016)
14) Reid, R. et al. Analytical and Simulation-Based Models for Drug Release and Gel-Degradation in a Tetra-PEG Hydrogel Drug-Delivery System. Macromolecules, 2015, 48, 7359-7369. (2015)
13) Schneider, E. et al. Half-Life Extension of the HIV-Fusion Inhibitor Peptide TRI-1144 Using a Novel Linker Technology. European Journal of Pharmaceuticals and Biopharmaceutics, 93, 254-259. (2015)
12) Henise, J. et al. Biodegradable Tetra-PEG Hydrogels as Carriers for a Releasable Drug Delivery System. Bioconjugate Chem, 26, 270-278. (2015)
11) Fontaine, S. et al. Long-Term Stabilization of Maleimide−Thiol Conjugates. Bioconjugate Chem., 26, 145-152. (2015)
10) Lawrence, M. et al. The Intravitreal Pharmacokinetics of Fluorophores Conjugated to PEGs by Non-Cleavable and Self-Cleaving Linkers in Non-human Primates. ARVO 2014 Annual Meeting. (2014)
9) Santi, D.V. et al. Macromolecular Prodrug that provides the Irinotecan Active-Metabolite SN-38 with Ultralong Half-Life, Low Cmax, and Low Glucuronide Formation. J.MedChem., 57, 2303-2314. (2014)
8) Schneider, E. et al. Beta-Eliminative Releasable Linkers Adapted for Bioconjugation of Macromolecules to Phenols. Bioconjugate Chem., 24, 1990-1997. (2013)
7) Henise, J. et al. An optimized hydrogel offers tunable half-life extension of peptides and proteins. Peptide Conference 2013.
6) Schneider, E.L., et al. Self-administered long-acting octreotide conjugates. Peptide Conference 2013.
5) Ashley, G.W. et al. Hydrogel drug delivery system with predictable and tunable drug release and degradation rates. PNAS, 110(6), 2318-2323. (2013)
4) Schneider, E.L. et al. Predictable half-life extension demonstrated through peptide TRI-1144. Peptide Conference 2012.
3) Henise, J. et al. A biodegradable hydrogel drug delivery system for tunable half-life extension. Peptide Conference 2012.
2) Santi, D.V. et al. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. PNAS, 109(16), 6211-6216. (2011)
1) Schneider, E. et al. Predictable and tunable drug release from macro-molecular conjugates. Peptide Conference 2011.
We have numerous issued US Patents and follow-on patent applications pending in the US and internationally. These claim advances in linker technology, the use of cleavable linkers in soluble circulating and solid supports, including hydrogels. Certain applications have claims directed towards specific therapeutic applications and compositions of matter.
Patent No. 11,454,861 | Hydrogels with biodegradable crosslinking | September 27, 2022
Patent No. 11,179,470 | Hydrogels with biodegradable crosslinking | November 23, 2021
Patent No. 11,181,803 | Hydrogels with biodegradable crosslinking | November 23, 2021
Patent No. 10,413,594 | Conjugates of somatostatin analogs | September 17, 2019
Patent No. 10,398,779 | Hydrogels with biodegradable crosslinking | September 3, 2019
Patent No. 10,342,792 | Slow-release conjugates of SN-38 | July 9, 2019
Patent No. 10,086,049 | Conjugates of somatostatin analogs | October 2, 2018
Patent No. 10,016,411 | Slow-release conjugates of SN-38 | July 10, 2018
Patent No. 9,649,385 | Claims on biodegradable hydrogels | May 16, 2017
Patent No. 9,387,254 | Claims on linkers | July 12, 2016
Patent No. 8,946,405 | Claims on linkers on solid supports | February 3, 2015
Patent No. 8,754,190 | Claims on adapted linkers for non-amines | June 17, 2014
Patent No. 8,703,907 | Claims on dendrimers with releasable linkers | April 22, 2014
Patent No. 8,680,315 | Claims on linkers, soluble conjugates | March 25, 2014